Table 1.

Bevacizumab studies in cervical cancer.

Study	Drug	n	Eligibility	Pathology	OS (months)	PFS (months)	RR (%)	Grade 3–4 AEs
Wright et al. [2006]	5-FU or capecitabine + bevacizumab (5-15 mg/kg IV Q3 weeks)	6	Retrospective series	Squamous, adenosquamous, poorly differentiated	5.1	NR	33	Neutropenia (17%), anemia (17%), thrombocytopenia (17%), fatigue (33%), diarrhea (17%), nausea (33%), bowel obstruction (17%)
Monk et al. [2009a]	bevacizumab 15 mg/kg Q3 weeks	46	Second line (74%); third line (26%); GOG PS 0-2	Squamous, adenosquamous	7.3	3.4	35	HTN (15%), thromboembolism (11%), anemia (4%), vaginal bleeding (2%), neutropenia (2%), pain (13%), GI (8.7%), cardiovascular (4.3%), pulmonary (2%), fistula (2%)
Schefter et al. [2014]	cisplatin 40 mg/m2+ radiation therapy + brachytherapy + bevacizumab 10 mg/kg Q2 weeks for 3 cycles	49	Untreated patients with stage 1B–3B cervical cancer	Squamous (80%)	3-year OS: 81.3%	3-year DFS 68.7%	NR	No treatment related SAEs; hematalogic AE 80%
Zighelboim et al. [2013]	cisplatin 50 mg/m2 day 1 + Topotecan 0.75 mg/m2 days 1, 2, 3 + bevacizumab 15 mg/kg day 1 Q3 weeks	27	First recurrence; GOG PS 0-1	Squamous (67%), adenocarcinoma (33%)	13.2	7.1	35	Leukopenia (74%), neutropenia (56%), thrombocytopenia (81%), anemia (63%), GI (19%), pain (33%), metabolic (48%), infection (19%)

AEs = adverse events; DFS = disease-free survival; GI = gastrointestinal; GOG = Gynecologic Oncology Group; HTN = hypertension; n = number of subjects; NR = not reported; OS = overall survival; PFS = progression-free survival; PS = performance status; Q = every; RR = response rate; SAE, serious adverse effect.